Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN NIVEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1336167634
CMS profile
60481
Location
MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$5.92

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $5.92 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $5.92 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN NIVEN

NPI 1336167634 · CMS profile ID 60481

Allopathic & Osteopathic Physicians / Dermatology

MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JOHN NIVEN, NPI 1336167634, CMS profile ID 60481, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $5.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $5.9210/22/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743814049 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $30.02 2
PY2020 $5.92 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020
Generated from
OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $547,115.16 88
PY2024 Principal investigator $919,823.31 487
PY2023 Recipient $1,200.00 1
PY2023 Principal investigator $635,503.38 419
PY2022 Principal investigator $475,737.00 87
PY2021 Principal investigator $161,162.86 33
PY2020 Principal investigator $161,071.72 49
PY2019 Principal investigator $202,395.85 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

420 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Arcutis Biotherapeutics, Inc. $6,832.60 12/04/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801425
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,842.06 12/04/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801525
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,500.00 12/04/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801561
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993573615
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993573617
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993573619
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993573621
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993573623
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574405
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574407
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574409
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574411
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574413
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574415
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574417
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574419
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574421
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574423
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574425
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574427
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574429
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574431
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574433
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574435
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574437
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574439
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574441
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574443
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574445
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574447
Principal investigator 1 Dermavant Sciences, Inc. $63.38 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574449
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574451
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574453
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574455
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574457
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574459
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574461
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574463
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574465
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574467
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574469
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574471
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574473
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574475
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574477
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574479
Principal investigator 1 Dermavant Sciences, Inc. $284.78 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574481
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574483
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574485
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574487
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574489
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574491
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574493
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574495
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574497
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574499
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574501
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574503
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574507
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574509
Principal investigator 1 Dermavant Sciences, Inc. $267.22 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574511
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574513
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574515
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574517
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574519
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574521
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574523
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574525
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574527
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574529
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574531
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574533
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574535
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574537
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574539
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574541
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574543
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574545
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574547
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574549
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574551
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574555
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574557
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574559
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574561
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574563
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574565
Principal investigator 1 Dermavant Sciences, Inc. $214.77 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574567
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574569
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574571
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574573
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574575
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574577
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574579
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574581
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574583
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574585
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574587
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574589
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574591
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574593
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574595
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574597
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574599
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574601
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574603
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574605
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574607
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574609
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574611
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574613
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574615
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574617
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574619
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574621
Principal investigator 1 Dermavant Sciences, Inc. $257.48 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574623
Principal investigator 1 Dermavant Sciences, Inc. $203.85 12/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993574625
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 11/30/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570733
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 11/30/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570735
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/30/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570737
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/30/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570739
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/30/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570741
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/30/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570743
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 11/30/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570747
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/30/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570749
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,655.68 11/07/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790381
Principal investigator 1 Arcutis Biotherapeutics, Inc. $209.95 11/06/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801489
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568629
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568631
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568633
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568637
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568639
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568641
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568643
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568645
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568647
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568649
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568651
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568653
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568655
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568659
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568661
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568663
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568665
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,418.00 11/01/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790357
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 11/01/2023 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period No dispute reported 06/30/2026 1039783387
Principal investigator 1 GENZYME CORPORATION $38,219.88 10/23/2023 Non-covered Recipient Entity
Lenus Research Medical Group LLC
Activ-POC - AD - Topical No dispute reported 06/30/2026 1035939087
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567827
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567831
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567833
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567835
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567837
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567839
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567841
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567843
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567845
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567847
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567849
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567853
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567855
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567857
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567859
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567861
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567863
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567865
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567867
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567869
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567871
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 10/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567875
Principal investigator 1 Arcutis Biotherapeutics, Inc. $962.20 10/04/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801461
Principal investigator 1 Arcutis Biotherapeutics, Inc. $4,071.42 10/04/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044814087
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 09/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564033
Principal investigator 1 Dermavant Sciences, Inc. $1,250.00 09/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564035
Principal investigator 1 Dermavant Sciences, Inc. $500.00 09/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564037
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 09/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564039
Principal investigator 1 Dermavant Sciences, Inc. $350.00 09/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564041
Principal investigator 1 Dermavant Sciences, Inc. $350.00 09/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564043
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 09/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564045
Principal investigator 1 Dermavant Sciences, Inc. $6,500.00 09/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564047
Principal investigator 1 Dermavant Sciences, Inc. $100.00 09/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564051
Principal investigator 1 Dermavant Sciences, Inc. $100.00 09/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564053
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,180.02 09/05/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801391
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,189.13 09/05/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044813955
Recipient Almirall LLC $1,200.00 08/31/2023 Covered Recipient Physician AD Survey testing No dispute reported 06/30/2026 1061983142
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $395.00 08/30/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790047
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563197
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563219
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563221
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563223
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563225
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563227
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563485
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563487
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563489
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563491
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563493
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563495
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563497
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563499
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563501
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 08/26/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563503
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,000.00 08/21/2023 Non-covered Recipient Entity
The University of Connecticut Health Center
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044820933
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,143.40 08/15/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790345
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $158.00 08/11/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053789805
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,434.80 08/01/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801331
Principal investigator 1 Arcutis Biotherapeutics, Inc. $147.60 08/01/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044814025
Principal investigator 1 Arcutis Biotherapeutics, Inc. $4,500.00 08/01/2023 Non-covered Recipient Entity
The University of Connecticut Health Center
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044820969
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $158.00 07/25/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053789793
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 07/21/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993560569
Principal investigator 1 Dermavant Sciences, Inc. $500.00 07/21/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993560571
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 07/21/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993560573
Principal investigator 1 Dermavant Sciences, Inc. $6,500.00 07/21/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993560575
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559737
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559739
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559741
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559743
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559745
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559747
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559749
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559751
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559753
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559755
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 07/15/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559757
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,089.00 07/14/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790333
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $395.00 07/12/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790037
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,063.88 07/04/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801361
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,327.64 07/04/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044813987
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,412.50 07/04/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044814057
Principal investigator 1 Almirall LLC $6,303.64 06/26/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
M14867-32 No dispute reported 06/30/2026 1061983250
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,089.00 06/21/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790319
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558697
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558699
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558701
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558703
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558705
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558707
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558709
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558713
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558715
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558717
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558719
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558721
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558723
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558725
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 06/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558727
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $316.00 05/31/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790025
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,726.00 05/31/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790107
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $79.00 05/30/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053789781
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,241.97 05/29/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801142
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,648.92 05/29/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801239
Principal investigator 1 Arcutis Biotherapeutics, Inc. $579.38 05/29/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044813817
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,205.96 05/29/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044813919
Principal investigator 1 Dermavant Sciences, Inc. $262.44 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557501
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557503
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557505
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557507
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557509
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557511
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557513
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557515
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557517
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557519
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557521
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557523
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 05/20/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557525
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,143.40 05/18/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790307
Principal investigator 1 Arcutis Biotherapeutics, Inc. $4,000.00 05/16/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044813781
Principal investigator 1 ABBVIE INC. $266.00 05/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 998382469
Principal investigator 1 ABBVIE INC. $1,215.00 05/02/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 998380035
Principal investigator 1 Almirall LLC $2,650.00 05/01/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
M14867-32 No dispute reported 06/30/2026 1061983248
Principal investigator 1 Arcutis Biotherapeutics, Inc. $5,208.28 05/01/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801177
Principal investigator 1 Arcutis Biotherapeutics, Inc. $6,283.37 05/01/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801209
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,657.55 05/01/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044813885
Principal investigator 1 Dermavant Sciences, Inc. $1,155.15 04/27/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993556077
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,052.34 04/20/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790297
Principal investigator 1 ABBVIE INC. $11,425.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 998378801
Principal investigator 1 Almirall LLC $480.00 04/17/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
M14867-32 No dispute reported 06/30/2026 1061983246
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $700.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128545
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,200.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128551
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $750.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128557
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $400.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128563
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $4,500.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128569
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $7,204.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128583
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $264.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128589
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $33.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128595
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $132.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128601
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $340.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128607
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $197.66 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128613
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $158.40 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128619
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $3,000.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128625
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $750.00 04/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128677
Principal investigator 1 Dermavant Sciences, Inc. $262.44 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554951
Principal investigator 1 Dermavant Sciences, Inc. $262.44 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554953
Principal investigator 1 Dermavant Sciences, Inc. $262.44 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554955
Principal investigator 1 Dermavant Sciences, Inc. $262.44 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554957
Principal investigator 1 Dermavant Sciences, Inc. $262.44 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554959
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554961
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554965
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554967
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554969
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554971
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554973
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554975
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554977
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554979
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554981
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554983
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554987
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554989
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554991
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554993
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554995
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554997
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554999
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555001
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555003
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555005
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555009
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555011
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555013
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555015
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555017
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555019
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555021
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/14/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555023
Principal investigator 1 ABBVIE INC. $17,376.61 04/13/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 998378347
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $79.00 04/10/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790013
Principal investigator 1 Dermavant Sciences, Inc. $359.12 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553967
Principal investigator 1 Dermavant Sciences, Inc. $359.12 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553969
Principal investigator 1 Dermavant Sciences, Inc. $359.12 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553971
Principal investigator 1 Dermavant Sciences, Inc. $359.12 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553973
Principal investigator 1 Dermavant Sciences, Inc. $359.12 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553975
Principal investigator 1 Dermavant Sciences, Inc. $1,514.28 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553977
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553979
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553981
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553983
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553985
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553987
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553989
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553991
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553993
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553995
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 04/07/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553997
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $8,838.20 04/05/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128575
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,100.00 04/03/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801107
Principal investigator 1 Arcutis Biotherapeutics, Inc. $811.33 04/03/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801266
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,648.92 04/03/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801303
Principal investigator 1 Arcutis Biotherapeutics, Inc. $981.00 04/03/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044813855
Principal investigator 1 SANOFI US SERVICES INC. $7,800.00 03/27/2023 Non-covered Recipient Entity
Interspond LLC
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 1036016191
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,193.68 03/24/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790283
Principal investigator 1 SANOFI US SERVICES INC. $9,683.00 03/20/2023 Non-covered Recipient Entity
Interspond LLC
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 1036015885
Principal investigator 1 ABBVIE INC. $2,269.50 03/16/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 998374189
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $395.00 03/14/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053789987
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $158.00 03/14/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053789999
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,858.00 03/10/2023 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis No dispute reported 06/30/2026 1053792145
Principal investigator 1 Arcutis Biotherapeutics, Inc. $4,449.17 02/27/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801011
Principal investigator 1 Arcutis Biotherapeutics, Inc. $6,283.37 02/27/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801079
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,089.00 02/27/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790273
Principal investigator 1 SANOFI US SERVICES INC. $4,000.00 02/21/2023 Non-covered Recipient Entity
Interspond LLC
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 1036015577
Principal investigator 1 Dermavant Sciences, Inc. $359.12 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551417
Principal investigator 1 Dermavant Sciences, Inc. $359.12 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551419
Principal investigator 1 Dermavant Sciences, Inc. $359.12 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551421
Principal investigator 1 Dermavant Sciences, Inc. $359.12 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551423
Principal investigator 1 Dermavant Sciences, Inc. $1,613.72 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551425
Principal investigator 1 Dermavant Sciences, Inc. $1,613.72 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551427
Principal investigator 1 Dermavant Sciences, Inc. $1,613.72 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551429
Principal investigator 1 Dermavant Sciences, Inc. $1,514.28 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551431
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551433
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551435
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551437
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551439
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551441
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551443
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551445
Principal investigator 1 Dermavant Sciences, Inc. $262.44 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551781
Principal investigator 1 Dermavant Sciences, Inc. $262.44 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551783
Principal investigator 1 Dermavant Sciences, Inc. $262.44 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551785
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551787
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551789
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551791
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551793
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551795
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551797
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551799
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551801
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 02/17/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551803
Principal investigator 1 ABBVIE INC. $798.00 02/16/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 998371025
Principal investigator 1 SANOFI US SERVICES INC. $6,580.00 02/13/2023 Non-covered Recipient Entity
Interspond LLC
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 1036015761
Principal investigator 1 ABBVIE INC. $9,878.00 02/09/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 998369465
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,738.18 01/31/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790259
Principal investigator 1 Arcutis Biotherapeutics, Inc. $7,273.04 01/30/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044800955
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,433.99 01/30/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044800981
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,505.16 01/30/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044813689
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $395.00 01/30/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053789965
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $158.00 01/30/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053789977
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,544.50 01/13/2023 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053790247
Principal investigator 1 Dermavant Sciences, Inc. $359.12 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549933
Principal investigator 1 Dermavant Sciences, Inc. $359.12 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549935
Principal investigator 1 Dermavant Sciences, Inc. $359.12 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549937
Principal investigator 1 Dermavant Sciences, Inc. $359.12 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549941
Principal investigator 1 Dermavant Sciences, Inc. $1,613.72 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549943
Principal investigator 1 Dermavant Sciences, Inc. $1,613.72 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549945
Principal investigator 1 Dermavant Sciences, Inc. $1,514.28 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549947
Principal investigator 1 Dermavant Sciences, Inc. $1,514.28 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549949
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549951
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549953
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549955
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549957
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549959
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549961
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550135
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550137
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550139
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550141
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 01/11/2023 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550143
Principal investigator 1 Almirall LLC $2,157.90 01/09/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
M14867-32 No dispute reported 06/30/2026 1061983242
Principal investigator 1 Almirall LLC $13,487.40 01/09/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
M14867-32 No dispute reported 06/30/2026 1061983244
Principal investigator 1 Arcutis Biotherapeutics, Inc. $15,580.33 01/09/2023 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044801045
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,066.56 01/09/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044813625
Principal investigator 1 Arcutis Biotherapeutics, Inc. $878.86 01/09/2023 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044813661